首頁 > 市場調查報告書 > 製藥

生物製劑

小分子藥物發現市場規模、佔有率和成長分析：按製程階段、技術、治療領域、藥物類型、工作流程、最終用戶和地區分類－2026-2033年產業預測

市場調查報告書

商品編碼

2036493

小分子藥物發現市場規模、佔有率和成長分析：按製程階段、技術、治療領域、藥物類型、工作流程、最終用戶和地區分類－2026-2033年產業預測

Small Molecule Drug Discovery Market Size, Share, and Growth Analysis, By Process Stage, By Technology, By Therapeutic Area, By Drug Type, By Workflow, By End-User, By Region - Industry Forecast 2026-2033

出版日期: 2026年05月05日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2024 年全球小分子藥物發現市場價值 700 億美元，預計從 2025 年的 756 億美元成長到 2033 年的 1,399.3 億美元，預測期（2026-2033 年）的複合年成長率為 8.0%。

技術創新是全球小分子藥物研發市場的主要驅動力，它加速了標靶識別和化合物最佳化，並推動該領域朝向數據驅動型發展。市場涵蓋小分子療法的發現、篩檢和先導化合物最佳化等多個階段。小分子療法因其生產成本低、可口服給藥等優點，通常能提高病患的用藥可及性。近年來，高通量篩檢和基於結構的藥物設計等技術進步，徹底改變了這項研發流程。計算化學與機器學習的整合是該市場成長的關鍵催化劑，它提高了命中率，降低了研發失敗率，從而促進了投資和合作。此外，人工智慧在先導藥物最適化的應用，簡化了候選化合物的選擇，提高了研發效率，並有助於拓展研發管線，尤其是在中樞神經系統（CNS）和腫瘤學等專業領域。

全球小分子藥物發現市場的促進因素

全球小分子藥物研發市場正受到篩檢技術進步的顯著推動。自動化、小型化以及具有更高預測準確性的改進型檢測方法等創新技術，使得小分子候選化合物的快速鑑定和最佳化成為可能。這些進步提高了實驗通量，增強了早期化合物的質量，最大限度地降低了後續階段的淘汰率，並使藥物化學領域的研究工作更加集中。此外，這些先進的篩檢平台能夠並行探索廣泛的化學領域，從而獲得全面的生物學見解。這有助於有效檢驗標靶，簡化先導化合物發現流程，推動全球投資，並加速藥物研發進程。

全球小分子藥物研發市場的限制因素

全球小分子藥物研發市場面臨許多挑戰，其中最嚴峻的挑戰在於複雜且不斷變化的監管要求，這增加了小分子候選化合物研發所需的時間和程序複雜性。對安全性、有效性和生產規範的嚴格要求，需要進行全面的臨床前表徵和詳盡的文件記錄，這往往導致與監管機構的長期溝通。這些要求會延誤專案進度，並將寶貴的資源轉移到合規措施。此外，對於試圖遵守各種地區法規和不斷變化的證據標準的小規模機構而言，策略柔軟性受到限制，導致候選化合物的研發速度減慢，並限制了小分子藥物研發領域的投資機會。

全球小分子藥物研發市場趨勢

全球小分子藥物研發市場正呈現出人工智慧驅動的標靶選擇和預測建模顯著融合的趨勢，從根本上改變了傳統的研發流程。這項進步透過將機器學習能力與人類專業知識結合，增強了虛擬篩檢、從頭設計和先導化合物最佳化等流程。因此，各機構能夠透過迭代學習，更聰明地選擇候選化合物並最佳化實驗設計。整合數據平台的激增正在推動對數據管治、多元化人才招募和可擴展計算基礎設施的投資，這些對於提高研究結果的可重複性和決策透明度，以及將計算洞察轉化為有效的藥物化學宣傳活動至關重要。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太國家
拉丁美洲
- 墨西哥
- 巴西
- 其他拉丁美洲國家
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲國家

競爭資訊

前五大公司對比
主要公司2025年的市場定位
主要市場公司採取的策略
近期市場趨勢
企業市場占有率分析，2025 年
主要公司的完整公司簡介
- 公司詳情
- 產品系列分析
- 按細分市場進行企業市佔率分析
- 銷售收入年比比較（2023-2025 年）

主要公司簡介

Pfizer Inc.
Novartis AG
Roche Holding AG
Merck & Co., Inc.
Johnson & Johnson
Bristol-Myers Squibb Company
AstraZeneca plc
Eli Lilly and Company
AbbVie Inc.
Takeda Pharmaceutical Company Limited
Charles River Laboratories
Evotec SE
WuXi AppTec
Syngene International Ltd.
ICON plc
Schrodinger Inc.
Exscientia plc
Recursion Pharmaceuticals Inc.
Insilico Medicine
BenevolentAI

結論與建議

簡介目錄

Product Code: UCMIG35H2224

Global Small Molecule Drug Discovery Market size was valued at USD 70.0 Billion in 2024 and is poised to grow from USD 75.6 Billion in 2025 to USD 139.93 Billion by 2033, growing at a CAGR of 8.0% during the forecast period (2026-2033).

Technological innovation is a key driver in the global small molecule drug discovery market, enhancing target identification and compound optimization while transitioning the field into a data-driven discipline. This market covers various stages, including discovery, screening, and lead optimization of low molecular weight therapeutics that are typically more cost-effective for manufacturing and offer oral administration, thus improving patient access. Recent advancements have transformed processes through high-throughput screening and structure-based designs. A significant growth catalyst lies in integrating computational chemistry and machine learning, which boost hit rates and reduce attrition, attracting investment and partnerships. Furthermore, the application of AI in lead optimization streamlines candidate selection, enhancing program efficiency and facilitating the expansion of pipelines, particularly into specialized areas such as CNS and oncology.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Small Molecule Drug Discovery market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Small Molecule Drug Discovery Market Segments Analysis

Global small molecule drug discovery market is segmented by process stage, technology, therapeutic area, drug type, workflow, end-user and region. Based on process stage, the market is segmented into Target Identification & Validation, Hit Generation, Lead Optimization and Preclinical Development. Based on technology, the market is segmented into High-Throughput Screening (HTS), Structure-Based Drug Design, Fragment-Based Drug Discovery and AI & Machine Learning. Based on therapeutic area, the market is segmented into Oncology, Cardiovascular Diseases, Neurology, Infectious Diseases and Metabolic Disorders. Based on drug type, the market is segmented into Traditional Small Molecules and Targeted Small Molecules. Based on workflow, the market is segmented into In Silico Drug Discovery, In Vitro Testing and In Vivo Studies. Based on end-user, the market is segmented into Pharmaceutical Companies, Biotechnology Companies and Contract Research Organizations (CROs). Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Small Molecule Drug Discovery Market

The Global Small Molecule Drug Discovery market is significantly driven by advancements in screening technologies. Innovations such as automation, miniaturization, and enhanced predictive assay formats allow for quicker identification and refinement of small molecule candidates. These developments boost experimental throughput and elevate the quality of early-stage compounds, thereby minimizing attrition rates in subsequent phases and allowing for more concentrated efforts in medicinal chemistry. Furthermore, these sophisticated screening platforms enable parallel exploration of a vast chemical landscape and yield comprehensive biological insights, which in turn facilitate effective target validation and streamline the hit-to-lead process, fostering investment and expediting drug discovery endeavors on a global scale.

Restraints in the Global Small Molecule Drug Discovery Market

The Global Small Molecule Drug Discovery market faces significant challenges due to intricate and constantly changing regulatory requirements that escalate both the time commitment and procedural complexities involved in advancing small molecule candidates. Stringent expectations concerning safety, efficacy, and manufacturing practices necessitate comprehensive preclinical characterization and meticulous documentation, often leading to extended interactions with regulatory bodies. These demands can hinder project timelines and redirect valuable resources toward compliance measures. Furthermore, for smaller organizations attempting to navigate various regional regulations and meet heightened evidentiary standards, strategic flexibility is hampered, resulting in slower candidate progression and consequently limiting investment opportunities in small molecule drug discovery efforts.

Market Trends of the Global Small Molecule Drug Discovery Market

The Global Small Molecule Drug Discovery market is witnessing a significant trend characterized by the integration of AI-driven target prioritization and predictive modeling, fundamentally transforming traditional workflows. This advancement enhances processes such as virtual screening, de novo design, and lead optimization by augmenting human expertise with machine learning capabilities. As a result, organizations are increasingly capable of making informed candidate selections and optimizing experimental planning through iterative learning from outcomes. The widespread adoption of integrated data platforms fosters improved reproducibility and decision transparency, prompting investments in data governance, diverse talent acquisition, and scalable computational infrastructures essential for translating computational insights into effective medicinal chemistry campaigns.

Introduction

Objectives of the Study
Market Definition & Scope

Research Methodology

Research Process
Secondary & Primary Data Methods
Market Size Estimation Methods

Executive Summary

Global Market Outlook
Key Market Highlights
Segmental Overview
Competition Overview

Market Dynamics & Outlook

Macro-Economic Indicators
Drivers & Opportunities
Restraints & Challenges
Supply Side Trends
Demand Side Trends
Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factors
Market Impacting Factors
Top Investment Pockets
Ecosystem Mapping
Market Attractiveness Index 2025
PESTEL Analysis
Regulatory Landscape
Value Chain Analysis
Case Studies
Technology Assessment
Customer & Buying Criteria Analysis
Pipeline Analysis
Disease Epidemiology

Global Small Molecule Drug Discovery Market Size by Process Stage & CAGR (2026-2033)

Market Overview
Target Identification & Validation
Hit Generation
Lead Optimization
Preclinical Development

Global Small Molecule Drug Discovery Market Size by Technology & CAGR (2026-2033)

Market Overview
High-Throughput Screening (HTS)
Structure-Based Drug Design
Fragment-Based Drug Discovery
AI & Machine Learning

Global Small Molecule Drug Discovery Market Size by Therapeutic Area & CAGR (2026-2033)

Market Overview
Oncology
Cardiovascular Diseases
Neurology
Infectious Diseases
Metabolic Disorders

Global Small Molecule Drug Discovery Market Size by Drug Type & CAGR (2026-2033)

Market Overview
Traditional Small Molecules
Targeted Small Molecules

Global Small Molecule Drug Discovery Market Size by Workflow & CAGR (2026-2033)

Market Overview
In Silico Drug Discovery
In Vitro Testing
In Vivo Studies

Global Small Molecule Drug Discovery Market Size by End-User & CAGR (2026-2033)

Market Overview
Pharmaceutical Companies
Biotechnology Companies
Contract Research Organizations (CROs)

Global Small Molecule Drug Discovery Market Size & CAGR (2026-2033)

North America (Process Stage, Technology, Therapeutic Area, Drug Type, Workflow, End-User)
- US
- Canada
Europe (Process Stage, Technology, Therapeutic Area, Drug Type, Workflow, End-User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Process Stage, Technology, Therapeutic Area, Drug Type, Workflow, End-User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Process Stage, Technology, Therapeutic Area, Drug Type, Workflow, End-User)
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa (Process Stage, Technology, Therapeutic Area, Drug Type, Workflow, End-User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche Holding AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Charles River Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Evotec SE
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
WuXi AppTec
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Syngene International Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ICON plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Schrodinger Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Exscientia plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Recursion Pharmaceuticals Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Insilico Medicine
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BenevolentAI
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments